SCTR regulates cell cycle-related genes toward anti-proliferation in normal breast cells while having pro-proliferation activity in breast cancer cells

Kang, Seongeun; Kim, Byungtak; Kang, Hyejin; Jeong, Gookjoo; Bae, Hansol; Lee, Hyun-Kyung; Lee, Seungyeon; Kim, Sun Jung

doi:10.3892/ijo.2015.3164

Cited by 13 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In physiological conditions, SCT binds to * * its receptor to mediate the effect of the gastrointestinal hormone on digestion and water homeostasis. e overexpression of SCT in MCF-7 cells led to an increase of the cell proliferation index and cellular migration [44]. e data of this study revealed the fact that miR-214-3p inversely acted on SCT in both MCF-7 and MDA-MB-231 cells.…”

Section: Discussionmentioning

confidence: 54%

“…However, whether SCT is an oncogene or a tumor suppressor is still controversial. A number of studies hold the idea that it is an oncogene, as high expression was observed in breast cancer [44], whereas other studies indicated the downregulation of the gene in colorectal cancer [45] and prostate cancer [46]. SCT acts as a gene with double-edge sword activities, which possesses both oncogenic and tumorsuppressive effects.…”

Section: Discussionmentioning

confidence: 99%

“…It plays a tumor-suppressive role in normal cells and a proliferation and migration stimulating role in cancer cells. It has been reported that SCT suppresses the proliferation of normal breast cells, while the gene stimulates the proliferation and migration of cancer cells [44].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Zhu

Hua

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

In this study, we aimed to evaluate the suppressive abilities of berberine (BBR) on MCF-7 and MDA-MB-231 cells and confirm its underlying mechanisms on miR-214-3p. We first built a panel of 18 miRNAs and 9 lncRNAs that were reported to participate in the mechanism of breast cancer. The RT-qPCR results suggested that BBR illustrated a dosage-dependent pattern in the stimulation to miR-214-3p in both MCF-7 and MDA-MB-231 cells. Then, we performed gain-and-lose function tests to validate the role of miR-214-3p contributing to the anticancer effects of BBR. Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively. However, miR-214-3p inhibitor counteracted all these effects of BBR. Based on the bioinformatics analysis and dual-luciferase reporter test, we identified binding sites between SCT and miR-214-3p. We further confirmed that BBR massively and dose-dependently reduced the mRNA expression and protein levels of SCT in both MCF-7 and MDA-231 cells. We testified that both miR-214-3p mimic and BBR could decrease the mRNA expression and protein levels of SCT, while miR-214-3p inhibitor weakened these reductions. In conclusion, BBR suppressed MCF-7 and MDA-MB-231 breast cancer cells by upregulating miR-214-3p and increasing its inhibition to SCT.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Zhu

Hua

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Upregulated GPCRs that have been proposed as therapeutic targets in cancer included the adenosine receptors ADORA1 and ADORA3 , and important GPCRs for autocrine growth factors in cancer, such as bombesin receptor NMBR , and neurotensin receptor NTSR1 45 , 46 . Additional GPCRs reported to promote proliferation and migration of cancer cells included secretin receptor SCTR , and lysophosphatidic acid (LPA) receptor LPAR2 47 , 48 . Finally, several upregulated hormone receptors were associated with the neuroactive receptor interaction pathway, including those for melanin-concentrating hormone, thyroid-stimulating hormone, calcitonin, corticotrophin-releasing hormone, follicle-stimulating hormone, luteinizing hormone beta, and glucagon-like peptide (Fig.…”

Section: Resultsmentioning

confidence: 99%

Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways

Granados-Soler

Taher

Beck³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The molecular heterogeneity of feline mammary carcinomas (FMCs) represents a prognostic and therapeutic challenge. RNA-Seq-based comparative transcriptomic profiling serves to identify recurrent and exclusive differentially expressed genes (DEGs) across sample types and molecular subtypes. Using mass-parallel RNA-Seq, we identified DEGs and performed comparative function-based analysis across 15 tumours (four basal-like triple-negative [TN], eight normal-like TN, and three luminal B fHER2 negative [LB fHER2−]), two cell lines (CL, TiHo-0906, and TiHo-1403) isolated from the primary tumours (LB fHER2−) of two cats included in this study, and 13 healthy mammary tissue controls. DEGs in tumours were predominantly upregulated; dysregulation of CLs transcriptome was more extensive, including mostly downregulated genes. Cell-cycle and metabolic-related DEGs were upregulated in both tumours and CLs, including therapeutically-targetable cell cycle regulators (e.g. CCNB1, CCNB2, CDK1, CDK4, GTSE1, MCM4, and MCM5), metabolic-related genes (e.g. FADS2 and SLC16A3), heat-shock proteins (e.g. HSPH1, HSP90B1, and HSPA5), genes controlling centrosome disjunction (e.g. RACGAP1 and NEK2), and collagen molecules (e.g. COL2A1). DEGs specifically upregulated in basal-like TN tumours were involved in antigen processing and presentation, in normal-like TN tumours encoded G protein-coupled receptors (GPCRs), and in LB fHER2− tumours were associated with lysosomes, phagosomes, and endosomes formation. Downregulated DEGs in CLs were associated with structural and signalling cell surface components. Hence, our results suggest that upregulation of genes enhancing proliferation and metabolism is a common feature among FMCs and derived CLs. In contrast, the dissimilarities observed in dysregulation of membrane components highlight CLs’ disconnection with the tumour microenvironment. Furthermore, recurrent and exclusive DEGs associated with dysregulated pathways might be useful for the development of prognostically and therapeutically-relevant targeted panels.

show abstract

“…an oncogene with an anti-proliferative effect in normal cells but a proliferation-stimulating activity in cancer cells (64). BBR was also found to exhibit its antitumor effects in MCF-7 and MDA-MB-231 BC cells via upregulating tumor suppressor microRNA (miR)-214-3p and reducing SCT level (63, 64).…”

Section: Dna Tata Box and Poly(a) Tailsmentioning

confidence: 99%

Berberine as a potential agent for breast cancer therapy

Zhong

Chen

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer (BC) is a common malignancy that mainly occurred in women and it has become the most diagnosed cancer annually since 2020. Berberine (BBR), an alkaloid extracted from the Berberidacea family, has been found with broad pharmacological bioactivities including anti-inflammatory, anti-diabetic, anti-hypertensive, anti-obesity, antidepressant, and anticancer effects. Mounting evidence shows that BBR is a safe and effective agent with good anticancer activity against BC. However, its detailed underlying mechanism in BC treatment remains unclear. Here, we will provide the evidence for BBR in BC therapy and summarize its potential mechanisms. This review briefly introduces the source, metabolism, and biological function of BBR and emphasizes the therapeutic effects of BBR against BC via directly interacting with effector proteins, transcriptional regulatory elements, miRNA, and several BBR-mediated signaling pathways. Moreover, the novel BBR-based therapeutic strategies against BC improve biocompatibility and water solubility, and the efficacies of BBR are also briefly discussed. Finally, the status of BBR in BC treatment and future research directions is also prospected.

show abstract

SCTR regulates cell cycle-related genes toward anti-proliferation in normal breast cells while having pro-proliferation activity in breast cancer cells

Cited by 13 publications

References 41 publications

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Transcription profiling of feline mammary carcinomas and derived cell lines reveals biomarkers and drug targets associated with metabolic and cell cycle pathways

Berberine as a potential agent for breast cancer therapy

Contact Info

Product

Resources

About